United Therapeutics (UTHR) RBC Capital Markets Global Healthcare Conference 2026 summary

Strategic initiatives and clinical progress

• Demonstrated strong clinical efficacy in two major trials: TETON-2 for IPF and ADVANCE OUTCOMES for PAH, both showing superior outcomes compared to previous studies.

• Revenue potential from these indications is expected to double the current run rate by the end of 2027, with significant long-term growth opportunities.

• Ongoing, positive engagement with the FDA, including recent advancements in organ manufacturing clinical trials, with no disruptions anticipated from regulatory leadership changes.

• Presentations at the American Thoracic Society meeting received strong enthusiasm, highlighting large opportunities in IPF and PAH.

Regulatory and product development updates

• Preparing an sNDA package for TYVASO in IPF, targeting submission by the end of summer, with hopes for priority review due to the magnitude of clinical benefit.

• TYVASO demonstrated convincing benefits as both monotherapy and add-on therapy in IPF, with potential for broad patient applicability.

• Exploring development of TYVASO DPI for IPF, with clinical pathway details to be finalized.

• TRESMI (treprostinil SMI) filing expected later this year for PAH and PH-ILD, with IPF expansion under consideration pending regulatory pathway clarification.

• Ralinepag DPI moving into phase I for PAH later this year, positioned as a potential best-in-class inhalable prostacyclin.

Financial outlook and market positioning

• Despite a light Q1 for TYVASO, double-digit top-line growth is guided for 2026, driven by the simplicity and dosing flexibility of TYVASO DPI.

• Commercial growth is anchored in PH-ILD and TYVASO DPI, with a $4 billion revenue run rate targeted by 2027.

• Doubling to an $8 billion run rate is anticipated with approvals for ralinepag in PAH and TYVASO nebulized in IPF, with additional contributions possible from pipeline products.

• Competitive differentiation centers on device delivery, deep lung penetration, and long-term physician and patient preference.

• Sales force expansion planned ahead of the IPF launch to increase market presence.